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INTRODUCTION
Herpes zoster is a common diagnosis in the emergency 
department (ED). Caused by the reactivation of the varicella-
zoster virus (VZV), zoster usually presents as a painful 
dermatomal rash. In addition to skin or mucosal involvement, 
VZV reactivation commonly affects the ophthalmic division 
of the trigeminal nerve and subsequently the eye. This 
manifestation is termed herpes zoster ophthalmicus (HZO). 
HZO is considered an ophthalmologic emergency, as sequelae 
often include severe chronic pain and vision loss. In order 
to ensure proper follow up and to minimize morbidity, the 
accurate and timely diagnosis of HZO in the ED is extremely 
important. While typically an easy diagnosis to make based 
on history and skin findings, occasionally HZO presents as an 
isolated ophthalmologic process that is difficult to distinguish 
from other more benign causes of a red eye.
CASE REPORT
A 64-year-old Chinese man presented to the ED with 
five days of increasingly blurry vision in his right eye. The 
blurring was associated with mild photophobia and a right-
sided headache which he described as a burning pain over 
his forehead. The patient did not wear corrective lenses and 
denied trauma, chemical exposure, discharge, foreign body 
sensation, sick contacts, or history of similar problems. 
Review of systems was positive for approximately one week 
of malaise, myalgia, and subjective fevers. The patient denied 
sore throat, rhinorrhea, hearing changes, rashes, or any other 
concerns. The patient did not know if he had ever had chicken 
pox or cold sores, and he denied any past medical problems, 
surgeries, allergies, or medications.
Physical exam revealed a well appearing male in no 
distress with vitals as follows: heart rate at 72 beats/minute, 
blood pressure at 145/84 mm Hg, respirations at 14 breaths/
minute, oral temperature at 36.8°C and room air oxygen 
saturation at 97%. HENT exam showed no obvious rashes 
or lesions; however, the patient had mild hyperesthesia 
over his right forehead. He had normal ear canals, tympanic 
membranes, nares, and oropharynx. The patient had no 
cervical or auricular lymphadenopathy.
Ophthalmologic exam was significant for slight right-
sided conjunctival irritation with no exudates or obvious 
corneal scarring. The patient had normal lids and consensual 
pupillary reflexes with mild discomfort on ipsilateral and 
contralateral pupillary testing. Extra-ocular motions were 
intact with no diplopia. Visual acuity was 20/20 in the left 
eye, 20/80 in the right, and 20/20 in both. Visual fields were 
normal and symmetric. Fundoscopic exam revealed normal 
appearing eye grounds with no evidence of hemorrhage, 
vascular occlusion, papilledema, or retinal detachment. 
Intraocular pressures were normal bilaterally. Anterior 
chamber slit lamp exam showed no corneal ulceration or 
cell and flare. Fluorescein staining yielded a 7mm branched 
dendritic corneal lesion (Figure 1). The remainder of his exam 
was unremarkable.
The patient was started on oral acyclovir and a topical 
cycloplegic. Ophthalmology was consulted, and the patient 
was discharged to ophthalmology clinic, where the ED 
findings were confirmed. In clinic the patient was started on 
Figure 1. Dendritic fluorescein uptake from Herpes zoster 
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topical steroids in addition to antivirals and cycloplegics, and 
was discharged home with early follow up by ophthalmology.
DISCUSSION
Varicella-zoster virus manifests itself as two distinct 
syndromes in humans. During primary infection, the virus 
causes chicken pox. After the initial infection, VZV remains 
latent in the dorsal root ganglia of sensory neurons, possibly 
reappearing as herpes zoster later in the patient’s life.
In the United States, VZV primary infection rate reaches 
nearly 100% by 60 years of age; however, this rate will likely 
decrease with the widespread usage of the VZV vaccine. The 
lifetime risk of varicella zoster is between 10-20% in patients 
who have had chicken pox. Risks for reactivation include any 
decline in the T-cell mediated immune response including that 
caused by normal aging, HIV/AIDS, and immunosuppressive 
medications.
Herpes zoster ophthalmicus is a relatively common 
presentation of zoster. By definition HZO is reactivation of 
VZV in the ophthalmic division of the trigeminal nerve (V1), 
and accounts for 10-25% of all herpes zoster cases.1 While 
HZO does not necessarily affect the structures of the eye, 
many of the acute and long-term complications associated 
with the disease are the result of direct viral toxicity to the 
eye or the ensuing inflammatory response within the eye. It is 
thought that approximately 50% of those diagnosed with HZO 
will develop complications. Many of these poor outcomes can 
be prevented or ameliorated with early recognition, treatment, 
and referral.
Classically, HZO begins with flu-like symptoms 
including fever, myalgia, and malaise for approximately one 
week. Typically, patients then develop a painful unilateral 
dermatomal rash in the distribution of one or more branches 
of V1: supraorbital, lacrimal, and nasocilliary. The skin 
manifestations usually begin as an erythematous macular 
rash, progressing over several days into papules, vesicles, 
and then pustules. These eventually rupture and scab, and in 
immunocompetent individuals will resolve over the course 
of two to three weeks. In about 60% of cases patients will 
complain of a painful dermatomal prodrome prior to the 
development of any rash. Ocular involvement is not invariable 
in HZO; however, in patients with nasocilliary nerve 
involvement (Hutchinson’s sign) some case series indicate 
100% go on to develop eye pathology.2 Approximately one 
third of those without nasocilliary involvement will eventually 
develop eye manifestations.3 Conversely, in a small subset 
of patients (such as our patient), ocular symptoms will 
predominate.4
Physical exam should include a thorough ophthalmologic 
exam including external inspection, visual acuity, visual fields, 
extra ocular movements, pupillary response, funduscopy, 
intraocular pressure, anterior chamber slit lamp exam, and 
corneal exam with and without staining. As in our patient, the 
differential diagnosis includes a broad range of pathology: 
herpes simplex keratitis, other viral or bacterial conjunctivitis, 
uveitis, glaucoma, trauma, chemical exposure, vascular 
occlusion, migraine, cluster headache, trigeminal neuritis, 
optic neuritis, vasculitis, and others. If the classic rash is 
present, a brief exam will limit this differential; however, as in 
our patient, this would not be adequate to diagnose a patient 
presenting with purely ocular involvement. Classic ocular 
involvement is typified by dendritic or punctate keratitis 
(Figure 1). This pattern of infection occurs in approximately 
65% of patients with HZO;4 however, other eye findings are 
more frequent and range from simple conjunctivitis to retinal 
necrosis and detachment. Any structure in the eye may be 
involved.4
Diagnostic testing is rarely indicated, as diagnosis can 
almost always be made by a combination of history and 
physical. It is possible to use a Tzanck smear or Wright 
stain to determine whether lesions contain herpes-type virus 
(though these will not differentiate between VZV and other 
herpes viruses). Viral culture, direct immunoflourescence 
assay, or PCR may also be used to confirm the diagnosis.
In the ED treatment consists of local wound care, pain 
control, initiation of antiviral medication, and antibiotics 
if needed. Acyclovir and other similar antivirals have been 
shown to significantly decrease adverse outcomes related 
to HZO if started within 72 hours of initial symptoms.5,6,7,8 
Studies report reduced pain during the outbreak, reduced 
likelihood of postherpetic neuralgia, increased rate of skin 
healing, decreased duration of viral shedding, and decreased 
incidence of corneal involvement. It is not proven that the 
patient accrues these benefits if the medications are started 
after the 72-hour window, but given the extremely low 
side-effect profile of the drugs and the serious sequelae of 
complications, most physicians recommend administering 
antivirals during the first seven to 10 days of symptoms.
Steroids (topical and systemic) may also play a role in 
the treatment of HZO. In some studies systemic steroids 
have been shown to speed skin healing and to decrease initial 
pain; however, there have been no definitive studies showing 
reduced long-term incidence of post-herpetic neuralgia or 
ocular complications.9,10 Likewise, topical steroids may 
be helpful in the initial management of pain due to uveitis 
or scleritis; however, they have a number of serious side 
effects and potential complications and should never be used 
without concomitant anti-viral treatment.4 Always obtain 
ophthalmologic consultation prior to starting steroid treatment.
Oral opiate and nonsteroidal anti-inflammatory 
medications are frequently indicated for pain and may be 
augmented by the use of cycloplegics in patients who display 
features of iritis.
In otherwise healthy individuals with minimal eye 
involvement, most sources suggest outpatient treatment 
with seven to 10 days of oral acyclovir at a dose of 800mg 
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five times daily. Other antiviral agents (valacyclovir 
and famciclovir) offer equivalent benefits and have 
reduced frequency of dosing, which may improve patient 
compliance. In high risk cases, admission for IV acyclovir 
is indicated. Admission is recommended for those with 
known immunodeficiency, patients on immunosuppressive 
medications, involvement of multiple dermatomes (which may 
indicate immunosuppression), retinal involvement, corneal 
ulceration, or serious bacterial superinfection. All patients 
with the possible diagnosis of HZO require ophthalmologic 
consultation prior to discharge from the ED in order to ensure 
full evaluation for more serious complications. For patients 
eventually discharged home, early ophthalmologic follow up 
is mandatory.
CONCLUSION
HZO is a potentially serious reactivation of VZV in the 
distribution of the ophthalmic division of the trigeminal nerve. 
Usually this entity presents with classic findings that make 
diagnosis simple; however, as was the case with our patient, 
HZO may easily be confused with more common and benign 
eye pathology. Full ophthalmologic exam is warranted in the 
patient with decreased vision or a red eye. Once the diagnosis 
of HZO is entertained, appropriate antiviral and adjunctive 
therapy should be initiated and ophthalmology consultation 
should be requested for evaluation and treatment of common 
complications.
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